The location of endogenous wild-type p53 protein in 293T and HEK293 cells expressing low-risk HPV-6E6 fusion protein with GFP

Acta Biochimica et Biophysica Sinica

Volumn 42, Issue 3, 2010, Pages 230-235

  Sun, Lina ^a   Shen, Xinxin ^a   Liu, Yan ^b   Zhang, Ge ^c,d   Wei, Jianchun ^a   Zhang, Huijuan ^a   Zhang, Enming ^a   Ma, Fengqin ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d SHANXI MEDICAL UNIVERSITY   (China)

Author keywords

Cytoplasm; E6; Endogenous wt p53; Green fluorescent protein; Human papillomavirus; Low risk

Indexed keywords

E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; ONCOPROTEIN; PROTEIN P53; REPRESSOR PROTEIN;

ARTICLE; CELL FRACTIONATION; CELL LINE; GENETICS; HUMAN; KIDNEY; METABOLISM;

CELL LINE; GREEN FLUORESCENT PROTEINS; HUMANS; KIDNEY; ONCOGENE PROTEINS, VIRAL; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SUBCELLULAR FRACTIONS; TUMOR SUPPRESSOR PROTEIN P53;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAMMALIA; PAPILLOMAVIRIDAE;

EID: 77249095340     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmq009     Document Type: Article

References (27)

1. Zur Hausen H. Papillomaviruses in human cancer. Cancer 1987, 59: 1692-1696. (Pubitemid 17075412)
2. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 21: 1129-1136.
3. Dupin N. Genital warts. Clin Dermatol 2004, 22: 481-486.
4. Werness BA, Levine AJ and Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248: 76-79.
5. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM and Lin D, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75: 817-825.
6. Xing C, Zhu B, Liu H, Yao H and Zhang L. Class I phosphatidylinositol 3-kinase inhibitor LY294002 activates autophagy and induces apoptosis through p53 pathway in gastric cancer cell line SGC7901. Acta Biochim Biophys Sin 2008, 40: 194-201.
7. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin DM, Newmeyer DD, Schuler M and Green DR. Direct activation of bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303: 1010-1014.
8. Chipuk JE, Maurer U, Green DR and Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 2003, 4: 371-381.
9. Stewart D, Ghosh A and Matlashewski G. Involvement of nuclear export in human papillomavirus type 18 E6 mediated ubiquitination and degradation of p53. J Virol 2005, 79: 8773-8783.
10. Sherman L and Schlegel R. Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. J Virol 1996, 70: 3269-3279.
11. Liang XH, Volkmann M, Klein R, Herman B and Lockett SJ. Co-localization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. Oncogene 1993, 8: 2645-2652.
12. Tao M, Kruhlak M, Xia S, Androphy E and Zheng ZM. Signals that dictate nuclear localization of human papillomavirus type 16 oncoprotein E6 in living cells. J Virol 2003, 77: 13232-13247.
13. Vaeteewoottacharn K, Chamutpong S, Ponglikitmongkol M and Angeletti PC. Differential localization of HPV16 E6 splice products with E6-associated protein. Virol J 2005, 2: 50.
14. Hiraiwa A, Kiyono T, Segawa K, Utsumi KR, Ohashi M and Ishibashi M. Comparative study on E6 and E7 genes of some cutaneous and genital papillomaviruses of human origin for their ability to transform 3Y1 cells. Virology 1993, 192: 102-111.
15. Li X and Coffino P. High-Risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 1996, 70: 4509-4516.
16. Chalfie M, Tu Y, Euskirchen G, Ward WW and Prasher DC. Green fluorescent protein as a marker for gene expression. Science 1994, 263: 802-805.
17. Bernat A, Massimi P and Banks L. Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. J Gen Virol 2002, 83: 829-833.
18. Gross-Mesilaty S, Reinstein E, Bercovich B, Tobias KE, Schwartz AL, Kahana C and Ciechanover A. Basal and human papillomavirus E6 oncoprotein -induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci USA 1998, 95: 8058-8063.
19. Ronco LV, Karpova AY, Vidal M and Howley PM. Human papillomavirus
20. E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998, 12: 2061-2072.
21. Kumar A, Zhao Y, Meng G, Srinivasan S, Delmolino LM, Gao Q and Dimri G, et al. Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol 2002, 22: 5801-5812.
22. Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sørlie T and Hovig E, et al. Database of p53 gene somatic mutations in human tumours and cell lines. Nucleic Acids Res 1994, 22: 3551-3555. (Pubitemid 24299821)
23. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997, 88: 323-331.
24. Xinarianos G, Liloglou T, Prime W, Sourvinos G, Karachristos A, Gosney JR and Spandidos DA, et al. p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. Int J Cancer 2002, 101: 248-252.
25. Kawamata H, Omotehara F, Nakashiro K, Uchida D, Shinagawa Y, Tachibana M and Imai Y, et al. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage. Int J Oncol 2007, 30: 1089-1097.
26. Nikolaev AY, Li M, Puskas N, Qin J and Gu W. Parc: A cytoplasmic anchor for p53. Cell 2003, 112: 29-40.
27. Mantovani F and Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2000, 20: 7874-7887.